Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0699790 (
colon cancer
)
28,837
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
CREPT
(Cell-cycle-related and expression-elevated protein in tumor)/RPRD1B, a novel protein that enhances the transcription of Cyclin D1 to promote cell proliferation during tumorigenesis, was demonstrated highly expressed in most of tumors. However, it remains unclear how
CREPT
is regulated in colorectal cancers. In this study, we report that miR-383 negatively regulates
CREPT
expression. We observed that
CREPT
was up-regulated but the expression of miR-383 was down regulated in both
colon cancer
cell lines and colon tumor tissues. Intriguingly, we found that enforced expression of miR-383 inhibited the expression of
CREPT
at both the mRNA and protein level. Using a luciferase reporter, we showed that miR-383 targeted the 3'-UTR of
CREPT
mRNA directly. Consistently we observed that over expression of miR-383 shortened the half-life of
CREPT
mRNA in varieties of colorectal cancer cells. Furthermore, restoration of miR-383 inhibited cell growth and colony formation of
colon cancer
cells accompanied by inhibition of expression of
CREPT
and related downstream genes. Finally, we demonstrated that stable over expression of miR-383 in
colon cancer
cells decreased the growth of the tumors. Our results revealed that the abundant expression of
CREPT
in colorectal cancers is attributed to the decreased level of miR-383. This study shed a new light on the potential therapeutic therapy strategy for colorectal cancers using introduced miRNA.
...
PMID:MicroRNA-383 acts as a tumor suppressor in colorectal cancer by modulating CREPT/RPRD1B expression. 2993 29